Gilead Bets On Broad Truvada Claim For HIV Risk Reduction
This article was originally published in Pharmaceutical Approvals Monthly
Gilead became the first sponsor to seek an indication for reducing the risk of HIV infection with an sNDA targeting the entire “uninfected adult” population, despite advocacy groups’ campaign for filing first for men who have sex with men.
You may also be interested in...
Keeping Track: 2021’s First Novel Approvals Go To HIV And Heart Failure Therapies Opdivo Starts Year With A Bang
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Even in the grip of the pandemic, review times for priority drugs were also consistent with the last three years.
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.